The tweet was deleted by the author.
But we saved everything 🙂.
Ornithine transcarbamylase (OTC) deficiency presents significant health risks when ammonia builds up in the body. Arcturus Therapeutics highlights the critical role OTC plays in the urea cycle and warns of the life-threatening symptoms that can arise if the enzyme's function is impaired.
The biotechnology firm emphasizes the urgency of addressing these deficiencies, which, if unrecognized, can lead to serious illnesses. With their expertise, Arcturus Therapeutics is voicing concerns to enhance awareness and urge further research into potential treatments and solutions.